PMA
BP140120: Bio-Rad Geenius HIV 1/2 Supplemental Assay
FDA PMA · Point of care hiv serology diagnostic and/or supplemental test · Bio-Rad Laboratories, Inc.
Key facts
| PMA number | BP140120 |
|---|---|
| Trade name | Bio-Rad Geenius HIV 1/2 Supplemental Assay |
| Generic name | Point of care hiv serology diagnostic and/or supplemental test |
| Applicant | Bio-Rad Laboratories, Inc. |
| Owner/operator | Bio-Rad Laboratories, Inc. |
| Product code | QSU |
| Approval date | Oct 24, 2014 |
| Establishment registration | 3003756338 |
| FEI number | 3003756338 |
At a glance
- 1–9 Supplements
- Nov 3, 2020 Latest supplement decision
- No Withdrawn
- No Summary of safety and effectiveness on file
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: